Published:
304
views
Singapore-headquartered biotech firm Mirxes launches Hong Kong IPO
The group expects to raise $1.08b.
Singapore biotech firm Mirxes has launched its initial public offering in Hong Kong, seeking to raise $1.08b.
The group is selling 46.62 million shares, 41,958,000 of the IPO offer will be available to international investors, whilst 4,662,000 shares are available to public subscription in Hong Kong.
“We estimate that we will receive net proceeds of approximately $887.6m after deducting the underwriting fees and expenses payable by us in the Global Offering, at the Offer Price of $23.30 per Offer Share,” the group said in its bourse filing to the HKEX.
Read Here
Advertise
Sign Up
